The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure services for the generation of a new Certificate of Analysis (CoA) for the drug conjugate PEN-866, which is critical for ongoing clinical trials involving pediatric and young adult cancer patients. The selected contractor will be responsible for conducting comprehensive testing and analysis under strict Current Good Manufacturing Practice (cGMP) regulations, ensuring the drug's stability and compliance throughout the trial period. PEN-866 is an important HSP90 inhibitor-drug-conjugate that has shown promise in tumor regression and survival improvement in various pediatric sarcoma models. Interested parties must submit their capability statements or proposals to Contracting Officer John Russell at John.Russell3@nih.gov by 10:00 A.M. EST on July 18, 2025, referencing notice number 75N91025Q00045. This acquisition will be processed as a sole source contract with PPD Development LP, the only vendor with established testing protocols for PEN-866.